These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30115524)

  • 1. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
    Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
    Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
    Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
    Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
    van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
    Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway.
    Feiring B; Laake I; Bakken IJ; Greve-Isdahl M; Wyller VB; Håberg SE; Magnus P; Trogstad L
    Vaccine; 2017 Jul; 35(33):4203-4212. PubMed ID: 28648542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of HPV vaccination delivery and equity in vaccine uptake: A nationwide cohort study.
    Wang J; Ploner A; Sparén P; Lepp T; Roth A; Arnheim-Dahlström L; Sundström K
    Prev Med; 2019 Mar; 120():26-33. PubMed ID: 30593796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
    Yoon D; Lee JH; Lee H; Shin JY
    BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mental illness and neurodevelopmental conditions in human papillomavirus vaccination uptake within the Swedish school-based vaccination programme: a population-based cohort study.
    Hu K; Barker MM; Herweijer E; Wang J; Feldman AL; Lu D; Valdimarsdóttir U; Sundström K; Fang F
    Lancet Public Health; 2024 Sep; 9(9):e674-e683. PubMed ID: 39214636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
    Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
    Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
    Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
    PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.
    Hviid A; Svanström H; Scheller NM; Grönlund O; Pasternak B; Arnheim-Dahlström L
    J Intern Med; 2018 Feb; 283(2):154-165. PubMed ID: 29044769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do parental education and income matter? A nationwide register-based study on HPV vaccine uptake in the school-based immunisation programme in Norway.
    Feiring B; Laake I; Molden T; Cappelen I; Håberg SE; Magnus P; Steingrímsdóttir ÓA; Strand BH; Stålcrantz J; Trogstad L
    BMJ Open; 2015 May; 5(5):e006422. PubMed ID: 25991445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.
    Mølbak K; Hansen ND; Valentiner-Branth P
    PLoS One; 2016; 11(9):e0162520. PubMed ID: 27611088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.